ENC1018

ENC1018 is a small molecule drug developed by EnnovaBio Australia Pharmaceuticals. It is currently in early clinical development, with its highest phase being Phase 1. The mechanism of action for ENC1018 has not been disclosed or remains unknown at this time. The drug is being investigated primarily for oral administration and has undergone first-in-human studies to evaluate its safety, tolerability, and pharmacokinetics in healthy adult subjects. There are also clinical trials exploring its use in patients with moderate-to-severe active ulcerative colitis[1][2][3][4]. No approved indications or known adverse events have been reported as of the latest updates.